International Stem Cell Corporation'
Cells to be used in the Development of Treatments for Liver Disease
Posted : Wed, 14 May 2008 13:41:53 GMT
OCEANSIDE, Calif. - (Business Wire) International Stem Cell
Corporation (OTCBB:ISCO) announced today that its human
parthenogenetic stem cell lines will be used in studies aimed at
creating liver cells to treat human liver disease.
The studies will be carried out under a Material Transfer Agreement
between ISCO and the University of California, San Francisco. Holger
Willenbring, MD, UCSF assistant professor of surgery, will direct the
research.
"The fact that Dr. Willenbring and the University of California at
San Francisco are testing the ability of ISCO's human parthenogenetic
stem cells to form liver cells is a strong validation of their
potential value in creating therapeutic cells that have significant
immune rejection advantages and significant ethical advantages," said
Jeffrey Janus, ISCO's President.
ISCO's human parthenogenetic stem cells are created from unfertilized
human eggs and do not involve the destruction of fertilized embryos,
yet share with conventional human embryonic stem cells the ability to
differentiate into all tissue types. They also are the first step in
solving one of the major obstacles to stem cell therapy, the
rejection of implanted cells by the patient's own immune system.
Human parthenogenetic stem cells will be expanded and differentiated
into liver cells in culture. The function and hence therapeutic value
of these liver cells will be tested by transplantation into an immune-
deficient mouse model of human liver disease.
A description of ISCO's human parthenogenetic stem cells and their
potential to solve critical immune rejection problems was reported in
ISCO's peer review paper published December 19, 2007 in the online
edition of Cloning and Stem Cells Journal:
http://www.lieberto
Elena Revazova, M.D., Ph.D., ISCO's Chief Scientific Officer,
stated, "ISCO has created a human parthenogenetic stem cell line
called phSC-Hhom-4. Cells derived from this line will not be immune
rejected after transplantation into millions of individuals of
differing sexes, ages and racial groups."
"Our business model," added Mr. Aldrich, ISCO's Chairman and CEO, "is
to make our cell lines and intellectual property easily available,
and thereby become a supplier of therapeutic cells for use by
patients around the world. To reach that goal, our intent is to
distribute our human parthenogenetic stem cell lines to as many
qualified researchers as possible so they may develop cures to as
many human diseases as rapidly as possible."
"As stem cell therapies using ISCO's human parthenogenetic stem cell
lines are advanced and approved by researches and regulatory
authorities, they will become an integral and recurring part of
future stem cell therapies that are brought to market," concluded Mr.
Janus.
The information stated above was prepared by ISCO. Nothing in this
statement shall be construed to imply any support or endorsement of
ISCO, or any of its products, by The Regents of the University of
California, its officers, agents and employees.
About International Stem Cell Corporation (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products.
ISCO's technology, parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will not be immune rejected after transplantation into millions
of individuals of differing sexes, ages and racial groups. These
advancements offer the potential to create the first true "Stem Cell
Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets
specialized cells and growth media worldwide for therapeutic research
through its subsidiary Lifeline Cell Technology. For more
information, visit the ISCO website at:
www.internationalst
To subscribe to receive ongoing corporate communications please click
on the following link: http://www.b2i.
BzID=1468&to=
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along
with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute forward-
looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such
as "will," "believes," "plans," "anticipates,
) should also be considered to be forward-looking statements. Forward-
looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results
of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property
rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should be
evaluated together with the many uncertainties that affect the
company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange Commission
filings. The company disclaims any intent or obligation to update
these forward-looking statements.
KEYWORDS: Stem Cells, Biotechnology, Parthenogenesis, Liver disease
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman, CEO, 760-940-6383
kaldrich@intlstemce
or
Jeffrey Janus, President, 760-940-6383
janusj@lifelinecell
http://www.earthtim
corporations-
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment